Table 3.
Characteristics of Patients With Breast Cancer and Multiple Myeloma
| Characteristics |
Breast cancer (N = 1338)
|
Multiple myeloma (N = 548)
|
||||
| Non-ONJ (N = 1322) | ONJ (N = 16) | p* | Non-ONJ (N = 535) | ONJ (N = 13) | p* | |
| Median age in years (minimum-maximum) | 57 (25–93) | 62 (44–79) | 0.3496 | 60 (28–88) | 64 (43–82) | 0.4796 |
| Median duration of bone metastases in years (minimum-maximum) | 2.02 (0–18.81) | 4.84 (0.8–11.03) | 0.0010 | NA | NA | NA |
| Median duration of disease in years (minimum-maximum) | 5.73 (0.03–37.48) | 7.27 (0.91–24.37) | 0.0801 | 3.18 (0–19.45) | 5.17 (1.73–13) | 0.0242 |
| Estrogen receptor status (yes/no) | 886/436 | 15/1 | 0.0284 | NA | NA | NA |
| Median does (mg) of bisphosphonate (minimum-maximum) | ||||||
| Pamidronate | 540 (45–9810) | 1710 (90–3510) | 0.0137 | 270 (30–9300) | 1800 (90–2520) | 0.0045 |
| Zoledronic acid | 32 (4–270) | 68 (8–132) | 0.0336 | 24 (4–172) | 58 (28–152) | 0.0158 |
| Median duration of treatment in years | ||||||
| Pamidronate | 0.59 (0.003–8.43) | 1.68 (0.90–4.24) | 0.0005 | 0.30 (0.003–6.70) | 1.55 (0.003–3.13) | 0.0104 |
| Zoledronic acid | 0.73 (0.003–4.07) | 2.04 (0.17–5.94) | 0.0004 | 0.67 (0.003–3.59) | 1.85 (0.74–2.92) | 0.0034 |
* p values were calculated with the use of the Fisher's exact tests or Wilcoxon rank-sum tests.
NA, not applicable.